Granisetron Production Cost Reports

The report provides a detailed analysis essential for establishing a Granisetron production plant. It encompasses all critical aspects necessary for Granisetron production, including the cost of Granisetron production, Granisetron plant cost, Granisetron production costs, and the overall Granisetron production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Granisetron production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Granisetron is a medication commonly used to prevent nausea and vomiting caused by cancer treatments like chemotherapy and radiation therapy. It works by blocking certain signals in the body that trigger the vomiting reflex. It is mainly used in the prevention and treatment of nausea and vomiting caused by chemotherapy, radiotherapy, and surgical procedures. It is commonly administered to cancer patients to improve comfort and treatment adherence during intensive therapy. It is also utilised in post-operative care to control anaesthesia-related nausea. It is available in several forms, including tablets, injections, and transdermal patches, which makes it convenient for different medical settings.

The market for Granisetron is mainly led by its application as an important medication to support oncology care and surgical recovery, which boosts its demand in the medical sector. Its application as an antiemetic agent in the treatment of nausea and vomiting associated with chemotherapy, radiation therapy, and surgeries significantly promotes its demand in the oncology and perioperative care sectors. Its application as a medication used before and after surgery to manage postoperative nausea also promotes its demand in the pharmaceutical and healthcare sectors. Its availability in various formulations, such as tablets, injections, and transdermal patches, to improve patient convenience and clinical outcomes, also contributes to its market demand.

Additionally, industrial Granisetron procurement is influenced by factors including the availability and cost of active pharmaceutical ingredients, regulatory approvals, production efficiency, and compliance with environmental and safety norms. Ongoing improvements in formulation technologies, supplier dependability, sustainable production methods, and streamlined supply chains also play a significant role in shaping its global procurement decisions.

Raw Material for Granisetron Production

According to the Granisetron production plant project report, the major raw materials for Granisetron production include 1-methyl-1H-indazole-3-carboxylic acid and (3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine.

Production Process of Granisetron

The extensive Granisetron production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of Granisetron begins with preparing the two main building blocks, including 1-methyl-1H-indazole-3-carboxylic acid and (3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine. The carboxylic acid is then activated into a reactive form, such as an acid chloride or ester, to make it ready for coupling. This activated acid reacts with the bicyclic amine under controlled conditions to form the amide bond, which forms the Granisetron base as the main product. The mixture is quenched and washed to remove impurities, followed by purification through extraction, crystallisation, or chromatography. Finally, the pure base converts to its hydrochloride salt, which is crystallised, filtered, and dried to produce the Granisetron hydrochloride as the final product.

Granisetron is a selective serotonin 5-HT3 receptor antagonist that appears as a white to yellowish white crystalline powder and is odourless. The molecular formula of the compound is C18H24N4O, and its molecular mass is 312.41 g/mol. It has a density of around 1.33 g/cm³, and the boiling point of the compound is approximately 532 degree Celsius at 760 mmHg. The compound is soluble in water and DMSO. The compound is metabolised primarily in the liver through oxidation followed by conjugation, with urinary excretion of unchanged drug averaging around 12% of the dose. The pKa value of the compound is 12.34. Moreover, the compound should be handled with appropriate safety precautions, and headache is reported as the most frequently occurring adverse effect associated with its use.